• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名45岁男性的脂蛋白(a)升高相关冠状动脉疾病

Elevated Lipoprotein(a)-Associated Coronary Artery Disease in a 45-Year-Old Male.

作者信息

Abeer Fatima, Wani Aasim A, Ahraz Ali

机构信息

Internal Medicine, Government Medical College, Srinagar, IND.

Chemical Engineering, National Institute of Technology, Srinagar, IND.

出版信息

Cureus. 2025 Apr 4;17(4):e81684. doi: 10.7759/cureus.81684. eCollection 2025 Apr.

DOI:10.7759/cureus.81684
PMID:40322355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12049667/
Abstract

Premature coronary artery disease (CAD) in younger adults often arises from underrecognized risk factors such as elevated lipoprotein(a) (Lp(a)), a genetically determined lipoprotein with atherogenic and prothrombotic properties. We report a 45-year-old male with untreated hypertension, prior ischemic stroke, and significant tobacco use, who presented with exertional angina. Laboratory evaluation showed mildly elevated low-density lipoprotein cholesterol (LDL-C; 142 mg/dL), borderline low high-density lipoprotein cholesterol (HDL-C; 38 mg/dL), and markedly elevated Lp(a) (180 mg/dL). Coronary angiography revealed a chronic total occlusion of the proximal left anterior descending (LAD) artery, 90% stenosis of the left circumflex (LCx) artery, and Rentrop grade 3 collateral flow from a codominant right coronary artery. Due to financial constraints, revascularization was deferred. The patient was managed with high-intensity statins, dual antiplatelet therapy, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and lifestyle modification. Over follow-up, he showed marked symptomatic improvement, enhanced left ventricular ejection fraction, and partial reversal of diastolic dysfunction. This case highlights the importance of Lp(a) screening in premature CAD and demonstrates that intensive medical therapy can stabilize high-risk patients when revascularization is not feasible.

摘要

年轻成年人的早发性冠状动脉疾病(CAD)通常源于未被充分认识的危险因素,如脂蛋白(a) [Lp(a)]升高,Lp(a)是一种具有致动脉粥样硬化和促血栓形成特性的遗传性脂蛋白。我们报告了一名45岁男性,患有未经治疗的高血压、既往缺血性中风且大量吸烟,因劳力性心绞痛就诊。实验室检查显示低密度脂蛋白胆固醇(LDL-C)轻度升高(142mg/dL),高密度脂蛋白胆固醇(HDL-C)临界低值(38mg/dL),Lp(a)显著升高(180mg/dL)。冠状动脉造影显示左前降支(LAD)近端慢性完全闭塞,左旋支(LCx)动脉90%狭窄,优势右冠状动脉的Rentrop 3级侧支血流。由于经济限制,血运重建被推迟。患者接受高强度他汀类药物、双联抗血小板治疗、β受体阻滞剂、血管紧张素转换酶(ACE)抑制剂治疗及生活方式改变。在随访期间,他的症状明显改善,左心室射血分数提高,舒张功能障碍部分逆转。该病例强调了Lp(a)筛查在早发性CAD中的重要性,并表明当血运重建不可行时,强化药物治疗可使高危患者病情稳定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47d2/12049667/38efcd3841bd/cureus-0017-00000081684-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47d2/12049667/38efcd3841bd/cureus-0017-00000081684-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47d2/12049667/38efcd3841bd/cureus-0017-00000081684-i01.jpg

相似文献

1
Elevated Lipoprotein(a)-Associated Coronary Artery Disease in a 45-Year-Old Male.一名45岁男性的脂蛋白(a)升高相关冠状动脉疾病
Cureus. 2025 Apr 4;17(4):e81684. doi: 10.7759/cureus.81684. eCollection 2025 Apr.
2
Case 270.病例270。
Radiology. 2019 Jun;291(3):811-813. doi: 10.1148/radiol.2019170821.
3
Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease.脂蛋白(a)和低密度脂蛋白胆固醇升高可预测早发冠心病患者血管造影病变的严重程度和复杂性。
J Clin Lipidol. 2018 Jul-Aug;12(4):1019-1026. doi: 10.1016/j.jacl.2018.03.090. Epub 2018 Apr 3.
4
Lipoprotein (a) interactions with cholesterol-containing lipids on angiographic coronary collateralization in type 2 diabetic patients with chronic total occlusion.脂蛋白 (a) 与 2 型糖尿病慢性完全闭塞患者造影冠状动脉侧支循环中含胆固醇脂质的相互作用。
Cardiovasc Diabetol. 2019 Jun 24;18(1):82. doi: 10.1186/s12933-019-0888-z.
5
Enhanced External Counterpulsation (EECP): An Evidence-Based Analysis.增强型体外反搏(EECP):基于证据的分析。
Ont Health Technol Assess Ser. 2006;6(5):1-70. Epub 2006 Mar 1.
6
Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severity.脂蛋白(a)升高对冠状动脉疾病表型和严重程度的影响。
Eur J Prev Cardiol. 2024 May 11;31(7):856-865. doi: 10.1093/eurjpc/zwae007.
7
Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients.脂蛋白(a)升高对冠状动脉血运重建患者预后的意义。
Int J Cardiol. 2013 Sep 1;167(5):1990-4. doi: 10.1016/j.ijcard.2012.05.007. Epub 2012 May 24.
8
[Comparative analysis of atherosclerotic plaque distribution in the left main coronary artery and proximal segments of left anterior descending and left circumflex arteries in patients qualified for percutaneous coronary angioplasty].[适合经皮冠状动脉介入治疗患者左冠状动脉主干及左前降支和左旋支近端节段动脉粥样硬化斑块分布的比较分析]
Ann Acad Med Stetin. 2006;52(2):51-62; discussion 62-3.
9
API expert consensus document on management of ischemic heart disease.缺血性心脏病管理的API专家共识文件
J Assoc Physicians India. 2006 Jun;54:469-80.
10
Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.稳定型冠状动脉疾病患者血浆磷脂酶A2浓度与脂蛋白亚组分之间的关系。
Clin Chim Acta. 2015 Jun 15;446:195-200. doi: 10.1016/j.cca.2015.04.032. Epub 2015 Apr 28.

本文引用的文献

1
Cardiovascular-Endocrine-Metabolic Medicine: Proposing a New Clinical Sub-Specialty Amid the Cardiometabolic Pandemic.心血管-内分泌-代谢医学:在心脏代谢大流行背景下提出一个新的临床亚专业。
Biomolecules. 2025 Mar 5;15(3):373. doi: 10.3390/biom15030373.
2
Inflammation in atherosclerotic cardiovascular disease: From diagnosis to treatment.动脉粥样硬化性心血管疾病中的炎症:从诊断到治疗。
Eur J Clin Invest. 2025 Jul;55(7):e70020. doi: 10.1111/eci.70020. Epub 2025 Mar 8.
3
Prevalence of Lipoprotein(a) Testing in a Contemporary Cohort.当代队列中脂蛋白(a)检测的患病率。
Circulation. 2025 Mar 4;151(9):649-651. doi: 10.1161/CIRCULATIONAHA.124.070361. Epub 2025 Mar 3.
4
A roadmap for empowering cardiovascular disease patients: a 5P-Medicine approach and technological integration.赋能心血管疾病患者的路线图:5P-医学方法与技术融合。
PeerJ. 2024 Aug 30;12:e17895. doi: 10.7717/peerj.17895. eCollection 2024.
5
Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now?缩小血脂异常管理指南与临床实践之间的差距:我们现在在哪里?
Expert Rev Cardiovasc Ther. 2024 Sep;22(9):441-457. doi: 10.1080/14779072.2024.2398444. Epub 2024 Sep 1.
6
Myocardial ischemia/reperfusion: Translational pathophysiology of ischemic heart disease.心肌缺血/再灌注:缺血性心脏病的转化病理生理学。
Med. 2024 Jan 12;5(1):10-31. doi: 10.1016/j.medj.2023.12.007.
7
Lipoprotein(a): a genetically determined risk factor for Cardiovascular disease.脂蛋白(a):心血管疾病的一种遗传决定风险因素。
Crit Rev Clin Lab Sci. 2023 Dec;60(8):560-572. doi: 10.1080/10408363.2023.2229915. Epub 2023 Jul 14.
8
Obesity, obesities and gastrointestinal cancers.肥胖症、肥胖和胃肠道癌。
Dis Mon. 2023 Dec;69(12):101592. doi: 10.1016/j.disamonth.2023.101592. Epub 2023 Jun 10.
9
Fundamental Pathobiology of Coronary Atherosclerosis and Clinical Implications for Chronic Ischemic Heart Disease Management-The Plaque Hypothesis: A Narrative Review.冠状动脉粥样硬化的基础病理生物学与慢性缺血性心脏病管理的临床意义——斑块假说:一个叙述性综述。
JAMA Cardiol. 2023 Feb 1;8(2):192-201. doi: 10.1001/jamacardio.2022.3926.
10
There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.迫切需要更早、更强化且更精准地治疗动脉粥样硬化性心血管疾病风险:当前实践综述及提高疗效的建议。
Am J Prev Cardiol. 2022 Aug 6;12:100371. doi: 10.1016/j.ajpc.2022.100371. eCollection 2022 Dec.